Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeticholic acid pharmacokinetic/pharmacodynamic study in PBC, NASH, and healthy volunteers
NL-OMON47216Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of obeticholic acid in primary biliary cholangitis (PBC) and metabolic dysfunction-associated steatohepatitis (MASH) (3 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoint: Effect on bile acid and lipid composition of bile and serum. Started Jul 2017; status: active, not recruiting.
02
Drugs
obeticholic acid
03
Conditions
primary biliary cholangitis (PBC)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NL-OMON47216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47216.